Notably, patients with low ITGB1 expression exhibited significantly low TIDE scores and significantly high response ratios (Figure 5D–F, p < 0.001), which may indicate that ITGB1 is a potential predictor of the efficacy of cancer immunotherapy in GC. The gene discussed is ITGB1; the disease is cancer.